Search research articles
Contact Us
Filters
Showing results (311-320 of 321) with videos related to
Page
of 33
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2005
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732
Harvey B Niell, James E Herndon, Antonius A Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
Vincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1997
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
M B Atkins, M J Robertson, M Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer
John V Heymach, Luis Paz-Ares, Filippo De Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2008
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
Mary E R O'Brien, Mark A Socinski, Alexander Y Popovich, et al.
Medical Oncology (Northwood, London, England)
|
August 24, 2010
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction
Nicholas W Choong, Ann M Mauer, Daniel C Haraf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
Thomas J Lynch, Philip D Bonomi, Charles Butts, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
April 11, 2023
Inflammation and DKK1-induced AKT activation contribute to endothelial dysfunction following NR2F2 loss
Edward J Dougherty, Li-Yuan Chen, Keytam S Awad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 22, 2006
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Novel agents in the treatment of lung cancer: conference summary statement
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Page
of 33
Search research articles
Search
Showing results (311-320 of 321) with videos related to
Sort By:
Page
of 33
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 1, 2005
Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732
Harvey B Niell, James E Herndon, Antonius A Miller, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
March 20, 2008
Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib
Vincent A Miller, Gregory J Riely, Maureen F Zakowski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 1, 1997
Phase I evaluation of intravenous recombinant human interleukin 12 in patients with advanced malignancies
M B Atkins, M J Robertson, M Gordon, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
October 22, 2008
Randomized phase II study of vandetanib alone or with paclitaxel and carboplatin as first-line treatment for advanced non-small-cell lung cancer
John V Heymach, Luis Paz-Ares, Filippo De Braud, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
July 3, 2008
Randomized phase III trial comparing single-agent paclitaxel Poliglumex (CT-2103, PPX) with single-agent gemcitabine or vinorelbine for the treatment of PS 2 patients with chemotherapy-naïve advanced non-small cell lung cancer
Mary E R O'Brien, Mark A Socinski, Alexander Y Popovich, et al.
Medical Oncology (Northwood, London, England)
|
August 24, 2010
Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction
Nicholas W Choong, Ann M Mauer, Daniel C Haraf, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference
Thomas J Lynch, Philip D Bonomi, Charles Butts, et al.
American Journal of Physiology. Lung Cellular and Molecular Physiology
|
April 11, 2023
Inflammation and DKK1-induced AKT activation contribute to endothelial dysfunction following NR2F2 loss
Edward J Dougherty, Li-Yuan Chen, Keytam S Awad, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 22, 2006
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 26, 2004
Novel agents in the treatment of lung cancer: conference summary statement
Thomas J Lynch, Alex A Adjei, Paul A Bunn, et al.
Page
of 33